Analysis of Factors Affecting Post Immunization Event (AEFI) of COVID-19 Vaccines in Indonesia: Online Survey
Abstract
Introduction: Cases of death and infection due to COVID-19 in Indonesia are the highest compared to other countries in Southeast Asia even though there are various types of Covid-19 vaccines in Indonesia. Although the Covid-19 vaccine has several benefits, there are side effects caused by vaccine administration (AEFI). Many studies have been conducted on AEFI of Covid-19 vaccine in the general public, but the number of studies that discuss special groups needs to be studied further.
Objective: This research aims to find out AEFI from more diverse community groups so that the results can be used as material for consideration in policy making.
Method: This type of research is a quantitative study with a research design using a cross-sectional study design and using the chi-square test. The sample amounted to 656 respondents who were taken using simple random sampling. Data collection was conducted in September 2023 based on a web survey through Google Forms. Questions regarding diet refer to the General Guidelines for Balanced Nutrition, sleep quality refers to the Pittsburgh Sleep Quality Index (PSQI), and anxiety refers to the Hamilton Rating Scale for Anxiety (HARS). Data will be processed using Stata 18 data processing application.
Result: There was no correlation between the factors studied and post-immunization adverse events (AEFI). However, history of atopic disease had an effect of 1.355 times greater than the dietary category which only had an effect of 0.725 times.
Conclusion: Factors associated with post-immunization adverse events (AEFI) such as socio-demographics, history of illness, diet and breakfast, history of allergic disease, history of atopic disease, history of anxiety, vaccine complaints, post-vaccine reactions did not have a significant association with AEFI.
References
Hidayat R, Mustika AP, Avisha F, Djuliannisaa Z, Winari DD, Putri RA, et al. Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel. Vaccines (Basel). 2022 Jun 1;10(6).
Santoso A, Sulistyaningrum IH, Fathnin FH, Rulin A, Nugrahaeni D, Rosyid A, et al. Analisis Perbedaan Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin Coronavac Dosis Pertama dan Kedua pada Masyarakat Provinsi Jawa Tengah Analysis of Difference in Adverse Events Following Immunization (AEFI) between First and Second Dose of Coronavac among Recidents in Central Java [Internet]. Vol. 19, Jurnal Farmasi Indonesia. 2022. Available from: http://journals.ums.ac.id/index.php/pharmacon
Zhao H, Li Y, Wang Z. Adverse event of Sinovac Coronavirus vaccine: Deafness. Vaccine. 2022 Jan 24;40(3):521–3.
Witka BZ, Wicaksono IA. Perbandingan Efikasi, Efisiensi, dan Keamanan Vaksin Covid-19 yang Akan Digunakan di Indonesia. Farmaka. 2021;19(2):48–59.
Fragkou PC, Dimopoulou D. Serious complications of COVID-19 vaccines: A mini-review. Metabol Open. 2021 Dec;12:100145.
Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: A systematic review and meta-analysis. Int Immunopharmacol. 2022 Aug 1;109.
Haider SMS, Alvi SA, Khan H, Majeed R, Syed T, Anwar A, et al. Common Side Effects of Pfizer COVID-19 Vaccine: An Experience From Pakistan. Cureus. 2023 Jun 24;
Fatimah M, Dianita E, Sitorus RJ, Supli ER, Alfredo AP. Determinant of Post COVID-19 Vaccination (Sinovac) Adverse Events Among Health Care Workers in Palembang. Jurnal Ilmu Kesehatan Masyarakat. 2022 Aug 2;13(2):180–96.
Ahamad MM, Aktar S, Uddin MJ, Rashed-Al-Mahfuz M, Azad AKM, Uddin S, et al. Adverse Effects of COVID-19 Vaccination: Machine Learning and Statistical Approach to Identify and Classify Incidences of Morbidity and Postvaccination Reactogenicity. Healthcare (Switzerland). 2023 Jan 1;11(1).
Yulyani V, Hasbie NF, Farich A, Valentine A. Hubungan Status Demografi, Komorbid Dengan KIPI Post Vaksin COVID-19 Pada Tenaga Kesehatan. Jurnal Ilmiah Kesehatan Sandi Husada. 2022 Jun 1;153–60.
Sari KSP, Martini M, Raningsih M. Hubungan Faktor Usia dengan Angka Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksinasi Covid-19 di SD Negeri 2 Kubutambahan. Jurnal Keperawatan Suaka Insan (JKSI). 2023;8(1):13–20.
Carhart-Harris RL, Nutt DJ. Serotonin and brain function: A tale of two receptors. Vol. 31, Journal of Psychopharmacology. SAGE Publications Ltd; 2017. p. 1091–120.
Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, et al. Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE—An Observational Study. Front Public Health. 2022 May 6;10.
Hartutik S, Lidiana HE. Kejadian Ikutan Pasca Imunisasi (KIPI) Pasca Vaksinasi Covid-19 di Wilayah Kerja Dinas Kesehatan Kota Surakarta. Jurnal Perawat Indonesia [Internet]. 2022;6(1):973–82. Available from: https://in.vaccine-safety-
Ichsan DS, Hafid F, Ramadhan K, Taqwin T. Determinan Kesediaan Masyarakat menerima Vaksinasi Covid-19 di Sulawesi Tengah. Poltekita?: Jurnal Ilmu Kesehatan. 2021 May 26;15(1):1–11.
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Vol. 24, Journal of Advanced Research. Elsevier B.V.; 2020. p. 91–8.
Simanjorang C, Juliana Surudani C, Budiman Makahaghi Y. Gambaran Awal Efek Samping Vaksin Sinovac-Coronavac pada Petugas Kesehatan di Kabupaten Kepulauan Sangihe. Jurnal Ilmiah Sesebanua. 2021;5(2):47–53.
Riad A, Pokorná A, Attia S, Klugarová J, Koš?ík M, Klugar M. Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021 Apr 1;10(7).
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb 1;21(2):181–92.
Lestari AF, Sitaresmi MN, Haspitaningrum A, Rachmasari KA, Wulandari R, Sari SK, et al. Adverse events following immunization (AEFIs) in health workers who receive COVID-19 vaccination at Academic Hospital Universitas Gadjah Mada, Yogyakarta. Indonesian Journal of Pharmacology and Therapy (IJPTher) [Internet]. 2023;04(1):1–10. Available from: https://doi.org/10.22146/ijpther.6860
Tanriover MD, Do?anay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet. 2021 Jul 17;398(10296):213–22.
Desnita R, Sapardi VS, Surya DO. JIK (Jurnal Ilmu Kesehatan) Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin Covid-19 Dosis Pertama dan Kedua. Jurnal Ilmu Kesehatan) [Internet]. 2022;6(1). Available from: https://jik.stikesalifah.ac.id
Andini A, Sididi M, Sartika, Abbas HH, Muhsanah F. Faktor Yang Berhubungan Dengan Kejadian Ikutan Pasca Imunisasi (KIPI) Pada Penerima Vaksin Sinovac. Window of Public Health Journal. 2022;3(4):728–40.
Setyoningsih H, Wicaksono TZ, Palupi DA. Identifikasi Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin Covid-19 pada Kelompok Komorbiditas di Desa Blaru Kecamatan Pati Kabupaten Pati. JPSCR: Journal of Pharmaceutical Science and Clinical Research. 2023 Dec 4;8(3):394.
Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine. 2021 Jun 1;36:1–6.
Koesnoe S. Teknis Pelaksanaan Vaksin Covid dan Antisipasi KIPI [Internet]. Jakarta; 2021 [cited 2024 May 7]. Available from: https://www.papdi.or.id/pdfs/1001/Dr%20Sukamto%20-%20Ws%20Vaksin%20Covid%20KIPI.pdf
Sampath V, Rabinowitz G, Shah M, Jain S, Diamant Z, Jesenak M, et al. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Vol. 76, Allergy: European Journal of Allergy and Clinical Immunology. John Wiley and Sons Inc; 2021. p. 1640–60.
Copyright (c) 2024 Media Publikasi Promosi Kesehatan Indonesia (MPPKI)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with Journal of Public Health and Pharmacy retain the copyright of their work. The journal applies a Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), which grants the following rights:
-
Copyright Retention: Authors retain the copyright of their work, maintaining full control over their intellectual property without restrictions.
-
Right of First Publication: Authors grant the journal the right of first publication of their work. This ensures that the work is initially published and credited in Journal of Public Health and Pharmacy.
-
License to Share and Reuse: The work is licensed under CC BY-SA 4.0, allowing others to copy, distribute, remix, and build upon the work for any purpose, even commercially, as long as proper credit is given to the authors, and any new creations are licensed under the same terms.
